Veozah vs CombiPatch / Climara Pro: How to Choose and Switch

What each drug actually does

Veozah and the combination patches reach the same destination, fewer new hot flashes, by completely different roads. Knowing the mechanism tells you a lot about who each option fits.

Veozah (fezolinetant): shutting off the thermostat signal

During menopause, falling estrogen causes neurons in the hypothalamus that produce neurokinin B (NKB) to fire excessively. Those NKB signals activate the KNDy neuron circuit, which then sends a false "overheat" alarm to your body's thermostat. Fezolinetant is a selective neurokinin 3 (NK3) receptor antagonist. It blocks NKB from binding to the NK3 receptor and quiets that misfiring circuit without adding any hormone to your system.

Because it contains no estrogen or progestin, Veozah does not affect the uterine lining, does not raise breast-tissue estrogenic activity, and does not require progestin co-administration for women with a uterus.

CombiPatch and Climara Pro: restoring estrogen directly

CombiPatch delivers estradiol 0.05 mg plus norethindrone acetate 0.14 mg per day through a twice-weekly adhesive patch. Climara Pro delivers estradiol 0.045 mg plus levonorgestrel 0.015 mg per day through a once-weekly patch. Both replace the estrogen your ovaries have stopped producing. The progestin component is included specifically to protect the endometrium: unopposed estrogen in a woman with a uterus carries a well-documented risk of endometrial hyperplasia and cancer, and adding a progestin reduces that risk back to baseline.

The transdermal route matters. Patches deliver estradiol directly into the bloodstream, bypassing first-pass liver metabolism. Oral estrogen increases hepatic production of clotting factors and sex-hormone-binding globulin; transdermal estradiol does not carry the same VTE risk increase seen with oral formulations.

Efficacy: what the trials actually measured

No head-to-head trial comparing fezolinetant directly with a combination patch exists. The comparison below synthesizes data from separate trials and should be read as contextual, not as proof that one drug outperforms the other across all women.

SKYLIGHT-1: fezolinetant's key evidence

The SKYLIGHT-1 trial, published in The Lancet in 2023, randomized 501 postmenopausal women with at least seven moderate-to-severe hot flashes per day to fezolinetant 30 mg, fezolinetant 45 mg, or placebo for 12 weeks. Both doses produced statistically significant reductions in hot-flash frequency and severity compared with placebo from week 1. At week 4, the 45 mg dose reduced moderate-to-severe hot flash frequency by approximately 3.0 episodes per day more than placebo. At week 12, that difference grew to roughly 3.5 episodes per day. The 30 mg dose showed a similar trajectory with a slightly smaller effect size.

Women in SKYLIGHT-1 were specifically postmenopausal. The trial did not include perimenopausal women or women still having cycles, so extrapolating to earlier stages is not supported by direct data.

Continuous combined transdermal HRT: established efficacy data

Studies of continuous combined estradiol-plus-progestin patches consistently show reductions in vasomotor symptom frequency of 70 to 90% compared with baseline, which generally exceeds the absolute reduction seen with fezolinetant in trials. Patches also address symptoms fezolinetant does not target: vaginal dryness, genitourinary syndrome of menopause (GSM), sleep disruption driven by estrogen deficiency, and bone density loss.

A 2003 randomized trial of continuous combined transdermal therapy demonstrated significant endometrial protection with no cases of hyperplasia at 12 months, confirming the safety of combined patches for women with a uterus.

What fezolinetant does not treat

Veozah is approved only for moderate-to-severe vasomotor symptoms. It has no effect on:

• Vaginal dryness or GSM
• Bone mineral density (no data showing preservation)
• Mood changes driven by estrogen deficiency
• Skin or hair changes related to low estrogen
• Urinary symptoms of GSM

If any of those symptoms are bothering you alongside hot flashes, a hormone-containing option addresses a broader range.

Side effects and safety profiles

Veozah: liver and the key monitoring requirement

The most clinically significant safety signal for fezolinetant is hepatotoxicity. In the SKYLIGHT program, elevated liver enzymes occurred in a small percentage of participants, and the FDA label requires liver function tests at baseline, then at 4 and 8 weeks, and at 3 months. Veozah is contraindicated in women with moderate or severe hepatic impairment. If your ALT or AST rises above five times the upper limit of normal, the drug should be stopped.

Other common side effects include abdominal pain (reported in roughly 5-11% of trial participants), diarrhea, insomnia, and back pain. Fezolinetant is also a CYP1A2 substrate: strong CYP1A2 inhibitors like fluvoxamine increase fezolinetant exposure significantly, and the combination is contraindicated.

CombiPatch / Climara Pro: hormonal risks in context

The risk conversation around combined HRT has evolved considerably since the original Women's Health Initiative reports. Current guidance from The Menopause Society is that for healthy women under 60, or within 10 years of menopause onset, the benefits of hormone therapy generally outweigh the risks for symptom management.

Specific risks to discuss with your clinician include:

• VTE (blood clots): Transdermal estradiol carries a lower VTE risk than oral estrogen, but combined patches with a progestin do carry some risk increase, particularly if you have other risk factors like obesity, smoking, or a personal or family history of clotting disorders.
• Breast cancer: The 2019 re-analysis from the Million Women Study and subsequent data suggest combined estrogen-progestin HRT carries a small but real increase in breast cancer risk with prolonged use. Micronized progesterone may carry lower risk than synthetic progestins, though the patches use synthetic progestins (norethindrone or levonorgestrel).
• Cardiovascular disease: Timing matters. Women who start HRT within 10 years of menopause and before age 60 show a neutral or favorable cardiovascular risk profile in most analyses.
• Skin reactions: Patch adhesives cause local irritation in 10-20% of users; rotating sites reduces this.

Pregnancy, lactation, and contraception

This section is mandatory reading if there is any chance you could become pregnant.

Fezolinetant (Veozah)

Veozah is contraindicated in pregnancy. Animal reproduction studies showed adverse developmental effects, and there are no adequate human pregnancy data. The FDA classifies fezolinetant as a drug that should not be used during pregnancy. If you are in perimenopause and still having cycles, even irregular ones, you may still be capable of ovulating. Veozah is not a contraceptive. Use a reliable contraceptive method concurrently if pregnancy is possible.

Lactation data are absent. Because the drug's effects on a nursing infant are unknown, breastfeeding is not recommended while taking fezolinetant.

CombiPatch and Climara Pro

Estradiol and progestin combination patches are contraindicated in pregnancy. Exogenous sex steroids are not safe for a developing fetus. Like fezolinetant, the patches provide no contraceptive effect. A perimenopausal woman who still has ovulatory cycles needs a separate contraceptive method, typically a non-hormonal option or a progestin-only method discussed with her clinician, because combined estrogen-progestin HRT formulations are not equivalent to combined hormonal contraceptives in their cycle-suppressive potency.

Estradiol passes into breast milk and may suppress lactation. Breastfeeding is not recommended while using these patches.

How each option fits your life stage

Perimenopause (still cycling irregularly)

Fezolinetant's trial data cover postmenopausal women only. Using it in perimenopause is off-label, and there is no direct evidence supporting efficacy or safety in women who are still cycling. Combination patches are used in late perimenopause, though the progestin component must be adequate to protect the endometrium if the uterine lining is still responding to estrogen.

Early postmenopause (within 10 years of last period, under 60)

Both options are studied and available in this window. The combination patch addresses a broader symptom set. Veozah is a reasonable choice for women who cannot or prefer not to use hormones.

Late postmenopause (more than 10 years post-menopause or over 60)

Starting hormone therapy for the first time in this window is generally not recommended per The Menopause Society 2022 position statement, because the risk-benefit profile shifts. Veozah's cardiovascular risk profile in this age group is not fully established, but the absence of hormonal activity makes it a more considered option for women for whom HRT is contraindicated.

Women with PCOS

PCOS is associated with insulin resistance and an elevated baseline metabolic risk. Neither fezolinetant nor the combination patches have been studied specifically in postmenopausal women with a history of PCOS. If you have PCOS and are entering menopause, metabolic monitoring should accompany either choice. The progestin types in these patches (norethindrone and levonorgestrel) have modest androgenic activity, which may be relevant if you had androgen-excess symptoms in your reproductive years.

Women with a history of estrogen-sensitive cancer

Veozah is the only option of these two that does not add systemic estrogen. For women with a personal history of breast cancer, endometrial cancer, or hormone-receptor-positive malignancy, combination patches are generally contraindicated. Fezolinetant does not stimulate estrogen-sensitive tissue and has emerged as a meaningful option in this group, though oncology input is required before starting. ACOG supports discussion of non-hormonal options for vasomotor symptoms in breast cancer survivors.

Who this is likely right for (and who it is not)

Veozah is likely a good fit if you:

• Have moderate-to-severe hot flashes as your primary complaint
• Cannot use estrogen (cancer history, high VTE risk, uncontrolled cardiovascular risk)
• Prefer a hormone-free approach
• Have normal liver function and are not taking strong CYP1A2 inhibitors
• Are confirmed postmenopausal (though off-label perimenopausal use is discussed case-by-case)

Veozah is not a good fit if you:

• Have moderate-to-severe liver disease
• Take fluvoxamine or other strong CYP1A2 inhibitors
• Also need relief from GSM, vaginal dryness, or bone protection
• Are pregnant, breastfeeding, or possibly pregnant without contraception

A combination patch is likely a good fit if you:

• Have hot flashes plus vaginal dryness, sleep disruption, or bone-density concerns
• Are in the healthy window for HRT (under 60, within 10 years of menopause)
• Have a uterus and need endometrial protection with your estrogen
• Prefer once-weekly (Climara Pro) or twice-weekly (CombiPatch) dosing over a daily pill

A combination patch is not a good fit if you:

• Have a personal history of estrogen-sensitive cancer
• Have active or recent VTE, coronary artery disease, or stroke
• Have unexplained vaginal bleeding
• Are pregnant, breastfeeding, or possibly pregnant without contraception
• Have significant liver disease

Switching between Veozah and a combination patch

Switching is medically straightforward but requires a plan. No washout period is mandated when switching from fezolinetant to a patch, because fezolinetant carries no hormonal activity and does not need to clear before estrogen is introduced. You can generally start the patch on the day you stop fezolinetant, though your clinician may choose to overlap briefly if your symptoms are severe.

Switching in the other direction, from a combination patch to Veozah, requires removing the patch and allowing it to clear (typically 1-2 days for the adhesive dose to dissipate) before starting fezolinetant. There is no pharmacological interaction between estradiol and fezolinetant that requires a long washout, but using both simultaneously is not an approved or studied combination.

A practical switching framework, developed for WomanRx clinical practice:

1. Confirm the reason for switching. Inadequate hot flash control? Side effects? New contraindication? The reason shapes the approach.
2. Check liver function before starting Veozah. If you are switching to fezolinetant from a patch, baseline LFTs are required before the first dose.
3. Review your current medications for CYP1A2 interactions before starting fezolinetant. Fluvoxamine, ciprofloxacin at higher doses, and some other drugs raise fezolinetant levels significantly.
4. If switching from Veozah to a patch and you still have a uterus, use a combined patch (estrogen plus progestin), not an estrogen-only patch, to protect the endometrium.
5. Expect a 4-week re-assessment window. Both fezolinetant and combination patches show measurable symptom change by week 4. If relief is inadequate at 4 weeks, a dose adjustment or alternative is worth discussing rather than staying on an ineffective regimen.
6. Update your contraception plan if you are perimenopausal. Neither drug prevents pregnancy.

Cost, access, and practical considerations

Veozah launched in the United States in 2023 at a list price of approximately $550 per month without insurance coverage. As a newer brand-name drug, it is not yet available as a generic. Insurance coverage varies widely; prior authorization citing failure of or contraindication to HRT is commonly required.

CombiPatch and Climara Pro are brand-name products with generic equivalents available for the norethindrone-containing patch formulations. Out-of-pocket costs with a generic are substantially lower, often under $100 per month, and many insurance plans cover them with standard cost-sharing.

Telehealth access differs by state. Fezolinetant requires liver function monitoring that some fully remote practices cannot easily coordinate. Combination patches are more routinely prescribed through telehealth menopause services.

The evidence gap: what we do not yet know

Women have been systematically underrepresented in drug trials for most of medical history, and menopause-specific research has its own gaps. A few things that remain unclear:

SKYLIGHT-1 included predominantly white participants; data in women of color, who experience higher rates of vasomotor symptom burden, are limited. The long-term safety of fezolinetant beyond 12 months of the open-label extension is still accumulating. The question of whether fezolinetant affects bone density, mood, or cognitive function over time has not been answered.

For the combination patches, the progestin-specific breast cancer risk question is not fully resolved. Most long-term data come from oral combined HRT; transdermal progestin data in large prospective cohorts are thinner.

Both drugs are also essentially unstudied in perimenopausal women who are still having cycles, a group with significant symptom burden who represent a large share of women seeking treatment.